Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria

Author:

Iriemenam Nnaemeka C.ORCID,Ige Fehintola A.,Greby Stacie M.,Mpamugo Augustine,Abubakar Ado G.,Dawurung Ayuba B.,Esiekpe Mudiaga K.,Thomas Andrew N.,Okoli Mary U.,Awala Samuel S.,Ugboaja Blessing N.,Achugbu Chicago C.,Odoh Ifeanyichukwu,Nwatu Felicia D.,Olaleye Temitope,Akayi Loveth,Akinmulero Oluwaseun O.,Dattijo Joseph,Onokevbagbe Edewede,Okunoye Olumide,Mba Nwando,Agala Ndidi P.,Uwandu Mabel,Aniedobe Maureen,Stafford Kristen A.ORCID,Abimiku Alash’le,Hamada Yohhei,Swaminathan Mahesh,Okoye McPaul I.,Steinhardt Laura C.,Audu RosemaryORCID

Abstract

Objective There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria. Methods Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Results The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%– 82.8%] and specificity was 99.0% [95% CI: 96.8%– 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%– 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213). Conclusions Our results showed overall lower sensitivity and a comparable specificity with the manufacturer’s validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.

Funder

U.S. President’s Emergency Plan for AIDS Relief

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference27 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3